Towards Drug Repositioning: A Unified Computational Framework for Integrating Multiple Aspects of Drug Similarity and Disease Similarity

In response to the high cost and high risk associated with traditional de novo drug discovery, investigation of potential additional uses for existing drugs, also known as drug repositioning, has attracted increasing attention from both the pharmaceutical industry and the research community. In this paper, we propose a unified computational framework, called DDR, to predict novel drug-disease associations. DDR formulates the task of hypothesis generation for drug repositioning as a constrained nonlinear optimization problem. It utilizes multiple drug similarity networks, multiple disease similarity networks, and known drug-disease associations to explore potential new associations among drugs and diseases with no known links. A large-scale study was conducted using 799 drugs against 719 diseases. Experimental results demonstrated the effectiveness of the approach. In addition, DDR ranked drug and disease information sources based on their contributions to the prediction, thus paving the way for prioritizing multiple data sources and building more reliable drug repositioning models. Particularly, some of our novel predictions of drug-disease associations were supported by clinical trials databases, showing that DDR could serve as a useful tool in drug discovery to efficiently identify potential novel uses for existing drugs.

[1]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[2]  Temple F. Smith,et al.  The statistical distribution of nucleic acid similarities. , 1985, Nucleic acids research.

[3]  Donald A. Wilson,et al.  ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models , 2012, Science.

[4]  Bruce T. Volpe,et al.  Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity , 2011, Proceedings of the National Academy of Sciences.

[5]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[6]  P. Sanseau,et al.  Computational Drug Repositioning: From Data to Therapeutics , 2013, Clinical pharmacology and therapeutics.

[7]  Cheng Zhu,et al.  Drug repositioning for orphan diseases , 2011, Briefings Bioinform..

[8]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[9]  Wentian Li,et al.  STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. , 2007, The New England journal of medicine.

[10]  Yongcui Wang,et al.  Drug Repositioning by Kernel-Based Integration of Molecular Structure, Molecular Activity, and Phenotype Data , 2013, PloS one.

[11]  Pankaj Agarwal,et al.  Systematic Drug Repositioning Based on Clinical Side-Effects , 2011, PloS one.

[12]  Fiona Crawford,et al.  Nilvadipine antagonizes both Aβ vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice , 2004, Brain Research.

[13]  Joel Dudley,et al.  Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..

[14]  Katya Scheinberg,et al.  Block Coordinate Descent Methods for Semidefinite Programming , 2012 .

[15]  Guanghui Hu,et al.  Human Disease-Drug Network Based on Genomic Expression Profiles , 2009, PloS one.

[16]  Zhiyong Lu,et al.  Pathway-based drug repositioning using causal inference , 2013, BMC Bioinformatics.

[17]  Hao Ye,et al.  Construction of Drug Network Based on Side Effects and Its Application for Drug Repositioning , 2014, PloS one.

[18]  Yanli Wang,et al.  PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..

[19]  Oakland J. Peters,et al.  Predicting new indications for approved drugs using a proteochemometric method. , 2012, Journal of medicinal chemistry.

[20]  Lin He,et al.  Prediction of Drug-Target Interactions for Drug Repositioning Only Based on Genomic Expression Similarity , 2013, PLoS Comput. Biol..

[21]  Patrick Aloy,et al.  Recycling side-effects into clinical markers for drug repositioning , 2012, Genome Medicine.

[22]  Zoran Obradovic,et al.  Computational Drug Repositioning by Ranking and Integrating Multiple Data Sources , 2013, ECML/PKDD.

[23]  R. Sharan,et al.  PREDICT: a method for inferring novel drug indications with application to personalized medicine , 2011, Molecular systems biology.

[24]  Fei Wang,et al.  Generalized Cluster Aggregation , 2009, IJCAI.

[25]  L. Cardon,et al.  Use of genome-wide association studies for drug repositioning , 2012, Nature Biotechnology.

[26]  Zhiyong Lu,et al.  A new method for computational drug repositioning using drug pairwise similarity , 2012, 2012 IEEE International Conference on Bioinformatics and Biomedicine.

[27]  A. Chiang,et al.  Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses , 2009, Clinical pharmacology and therapeutics.

[28]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[29]  Hsiang-Yuan Yeh,et al.  Inferring drug-disease associations from integration of chemical, genomic and phenotype data using network propagation , 2013, BMC Medical Genomics.

[30]  Xiang Li,et al.  DOSim: An R package for similarity between diseases based on Disease Ontology , 2011, BMC Bioinformatics.

[31]  S. Trent Rosenbloom,et al.  Categorical Information in Pharmaceutical Terminologies , 2006, AMIA.

[32]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[33]  Lin He,et al.  DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical–protein interactome , 2011, Nucleic Acids Res..

[34]  Jing Wang,et al.  Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. , 2012, Cell stem cell.

[35]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[36]  Gang Feng,et al.  Disease Ontology: a backbone for disease semantic integration , 2011, Nucleic Acids Res..

[37]  Yan Zhao,et al.  Drug repositioning: a machine-learning approach through data integration , 2013, Journal of Cheminformatics.

[38]  K. Śmietana,et al.  Outlook for the next 5 years in drug innovation , 2012, Nature Reviews Drug Discovery.

[39]  R. Jiang,et al.  Integrating human omics data to prioritize candidate genes , 2013, BMC Medical Genomics.

[40]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..

[41]  G. Vriend,et al.  A text-mining analysis of the human phenome , 2006, European Journal of Human Genetics.

[42]  C E Lipscomb,et al.  Medical Subject Headings (MeSH). , 2000, Bulletin of the Medical Library Association.

[43]  Yadi Zhou,et al.  Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic methods. , 2012, Molecular bioSystems.

[44]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[45]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.